139 related articles for article (PubMed ID: 4038655)
1. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
Preisler HD; Rustum Y; Priore RL
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Preisler HD; Rustum YM; Azarnia N; Priore R
Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
[TBL] [Abstract][Full Text] [Related]
3. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
4. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.
Jamieson GP; Snook MB; Wiley JS
Leuk Res; 1990; 14(5):475-9. PubMed ID: 2345470
[TBL] [Abstract][Full Text] [Related]
5. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
Wiley JS; Taupin J; Jamieson GP; Snook M; Sawyer WH; Finch LR
J Clin Invest; 1985 Feb; 75(2):632-42. PubMed ID: 3871794
[TBL] [Abstract][Full Text] [Related]
6. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
Rustum YM; Preisler HD
Cancer Res; 1979 Jan; 39(1):42-9. PubMed ID: 282940
[No Abstract] [Full Text] [Related]
7. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Plunkett W; Iacoboni S; Keating MJ
Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
[No Abstract] [Full Text] [Related]
8. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
[TBL] [Abstract][Full Text] [Related]
9. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
Jamieson GP; Finch LR; Snook M; Wiley JS
Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
[TBL] [Abstract][Full Text] [Related]
10. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
11. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
Tanaka M; Yoshida S
Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
[TBL] [Abstract][Full Text] [Related]
12. Two simple high-performance liquid chromatographic methods for simultaneous determination of 2'-deoxycytidine 5'-triphosphate and cytosine arabinoside 5'-triphosphate concentrations in biological samples.
Danks MK
J Chromatogr; 1982 Dec; 233():141-8. PubMed ID: 7161328
[TBL] [Abstract][Full Text] [Related]
13. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.
Preisler HD; Epstein J; Raza A; Azarnia N; Browman G; Booker L; Goldberg J; Gottlieb A; Brennan J; Grunwald H
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1061-8. PubMed ID: 6540689
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Paul CY; Gahrton CG; Peterson CO
Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
[TBL] [Abstract][Full Text] [Related]
16. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia.
Wiley JS; Woodruff RK; Jamieson GP; Firkin FC; Sawyer WH
Aust N Z J Med; 1987 Aug; 17(4):379-86. PubMed ID: 3501710
[TBL] [Abstract][Full Text] [Related]
17. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
Wiley JS; Jones SP; Sawyer WH; Paterson AR
J Clin Invest; 1982 Feb; 69(2):479-89. PubMed ID: 6948829
[TBL] [Abstract][Full Text] [Related]
18. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Plunkett W; Keating M
Adv Exp Med Biol; 1986; 195 Pt B():171-5. PubMed ID: 3766228
[No Abstract] [Full Text] [Related]
19. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologically directed design of leukemia therapy.
Plunkett W; Heinemann V; Estey E; Keating M
Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
